Ezose Sciences and Hirosaki University to Collaborate in Glycomics Research
Complete the form below to unlock access to ALL audio articles.
Ezose Sciences Inc. and Hirosaki University have announced that they have formed a collaboration in glycomics research to identify new biomarkers for use in predicting and monitoring the progression of prostate cancer and other urological cancers.
The research will examine serum and urine samples collected by Hirosaki clinical investigators from well-characterized patient and control populations in Japan.
Ezose will conduct the glycan analysis at its US laboratories using its proprietary GlycanMap® technology platform.
“This agreement marks another step that scientists at Ezose and in universities are taking together to improve our understanding of the role of glycans in health and disease,” said Hidehisa Asada, Ph.D., Vice President, Research & Development at Ezose.
Asada continued, “Given the already established clinical utility of glycan-based biomarkers in certain cancers, we believe that further studies in oncology hold promise for identifying other novel biomarkers that could help guide clinical practice.”
Chikara Ohyama, M.D., Ph.D., Professor and Chairman, Department of Urology at the Hirosaki University Graduate School of Medicine, said: “Glycomics is beginning to come into its own as a basic tool in biomedical research. We look forward to applying this new technology to unmet medical needs in managing urologic cancers through the complementary contributions of Ezose’s scientists and our own.”
Under terms of the agreement, Ezose is granted exclusive rights by Hirosaki University to develop and commercialize new biomarkers resulting from the collaboration.
